Adam Woodrow
Net Worth
Last updated:
What is Adam Woodrow net worth?
The estimated net worth of Mr. Adam Woodrow is at least $6,434,560 as of 21 Dec 2022. He has earned $739,600 from insider trading and has received compensation worth at least $5,694,960 in Paratek Pharmaceuticals, Inc..
What is the salary of Adam Woodrow?
Mr. Adam Woodrow salary is $711,870 per year as Pres & Chief Commercial Officer in Paratek Pharmaceuticals, Inc..
How old is Adam Woodrow?
Mr. Adam Woodrow is 58 years old, born in 1967.
What stocks does Adam Woodrow currently own?
As insider, Mr. Adam Woodrow owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Paratek Pharmaceuticals, Inc. (PRTK) | Pres & Chief Commercial Officer | 651,284 | $0 | $0 |
What does Paratek Pharmaceuticals, Inc. do?
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
Adam Woodrow insider trading
Paratek Pharmaceuticals, Inc.
Mr. Adam Woodrow has made 23 insider trades between 2017-2022, according to the Form 4 filled with the SEC. Most recently he sold 6,750 units of PRTK stock worth $13,433 on 21 Dec 2022.
The largest trade he's ever made was exercising 22,624 units of PRTK stock on 15 Dec 2021. As of 21 Dec 2022 he still owns at least 651,284 units of PRTK stock.
Paratek Pharmaceuticals key executives
Paratek Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. Evan Loh (66) Chief Executive Officer & Director
- Mr. Adam Woodrow (58) Pres & Chief Commercial Officer
- Mr. Michael F. Bigham CPA, CPA, M.B.A., MBA (67) Executive Chairman